INTRODUCTION
Amygdalin is a naturally occurring plant glycoside found mainly in the seeds of apricots and bitter almonds. It is one of the most controversial natural substance that has been used as an anticancer drug for long period. This bioactive compound is composed of glucose, benzaldehyde, which induces an analgesic action, and hydrocyanic acid, which is an anti-neoplastic compound (Fukuda et al., 2003; Chang et al., 2006) . Amygdalin (C20H27NO11, Fig. 1A ) is many times confused with laevomandelonitrile, which is commonly known as Laetrile (C14H15NO7, Fig. 1B ). However, amygdalin and laetrile are different chemical compounds (Andrew et al., 1980; Du et al., 2005) . Since the early 1950s, a modified form of amygdalin has been developed under the names "laetrile" and "Vitamin B17" to cure cancer, but it is not a vitamin. Studies have found it to be ineffective, dangerously cause cyanide posisoning, and sometimes fatal under realistic conditions (Zhou et al., 2012). The decomposition of amygdalin is catalyzed by the action of β-D-glucosidase to yield hydrocyanic acid which stimulates the respiratory center and has antitussive and antiasthmatic effects (Badr and Tawfik, 2010; Lv et al., 2005) . β-glucosidase, one of the enzymes that catalyzes the release of cyanide from amygdalin, is present in the human small intestine and is also found in a variety of common foods (Strugala et al.,
1995; Deng et al., 2002).
Amygdalin is one of pharmacological components of crude ingredients of Keishibukuryo-gan, Japanese herbal medicine (Yasui et al., 2003) . It has been used for induction of ovulation in women suffering from infertility (Igarashi, 1988) . Keishi-bukuryo-gan and its crude ingredients affected steroidogenesis in preovulatory follicles (Usuki, 1987 (Usuki, , 1990 (Usuki, , 1991 and the corpus luteum (Usuki, 1986 (Usuki, , 1988 in the rat ovary in vivo and in vitro. Many studies have reported that amygdalin can be effectively used for prevent and treat various diseases including cancers, migraine, chronic inflammation, relieve fever and pain (Yan et (Mahajan, 2008) . In the present report, release of the steroid hormones (progesterone and estradiol-17β) by healthy porcine ovarian granulosa cells after amygdalin treatment (various doses) was observed. 
MATERIAL AND METHODS

Preparation, culture and processing of granulosa cells from ovaries
Ovaries from cyclic pigs were obtained from healthy Slovakian White gilts without obvious reproductive abnormalities. The ovaries were transported to the laboratory in containers at 4 ºC and washed in sterile physiological solution. The follicular fluid was aspirated from 3-5 mm follicles. The granulosa cells (GCs) Amygdalin, a natural substance, is a cyanogenic glycoside occurring in the seeds of apricots and bitter almonds. It is a controversial antitumor compound that has been used as an alternative cancer drug for many years. Amygdalin is composed of two molecules of glucose, one of benzaldehyde, which induces an analgesic action, and one of hydrocyanic acid, which is an anti-neoplastic compound. This in vitro study was performed to evaluate the possible impact of amygdalin (1, 10, 100, 1000, 10 000 µg/mL) on the secretory activity of granulosa cells (GCs) from porcine cyclic ovaries. The release of progesterone and estradiol-17β by GCs were evaluated by ELISA. In our study, the noticeable changes in estradiol-17β release by ovarian GCs were determined after the amygdalin addition. Amygdalin, at the highest dose (10 000 µg/mL), significantly (P≤0.05) stimulated the release of estradiol-17β by GCs, in comparison to the untreated control cells. On the contrary, no significant (P≥0.05) changes in the progesterone release by GCs caused by amygdalin addition were observed. In conclusion, obtained results showed that the amygdalin application (various doses) to ovarian GCs caused a dose-dependent stimulation of the estradiol-17β release, but not progesterone, and its possible modulatory impact on the steroid production in porcine ovaries.
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were isolated by centrifugation for 10 min at 200xg followed by washing in sterile DMEM/F12 1:1 medium (BioWhittaker TM , Verviers, Belgium) and resuspended in the same medium supplemented with 10% fetal calf serum (BioWhittaker TM , Verviers, Belgium) and 1% antibiotic-antimycotic solution (Sigma, St. Louis, Mo, USA) at the final concentration of 10 6 cells/mL (as detected by a haemocytometer). Portions of the cell suspension were dispensed to 24-welled culture plates (Nunc TM , Roskilde, Denmark, 1ml/well; for Enzyme Linked Immuno Sorbent Assay, ELISA). The well plates were incubated at 37 °C and 5% CO2 in humidified air until a 75% confluent monolayer was formed (4-5 days), at this point, the medium was renewed and ovarian granulosa cells were incubated with the same supplements (DMEM/F12 1:1 medium, 10% fetal calf serum, without 1% antibiotic-antimycotic solution) and without (control) or with amygdalin (1, 10, 100, 1000, 10 000 µg/mL) (≥99 % purity, from apricot kernels, Sigma-Aldrich, St. Louis, Mo, USA) for 24h. After 24h of incubation the culture media from well plates were aspirated and kept at -80°C for subsequent assay. The concentrations of steroid hormones progesterone and estradiol-17β were assayed using ELISA (Dialab, Wiener Neudorf, Austria) according to the manufacturer´s instructions.
Statistical Analysis
Each experimental group was represented by four culture wells of granulosa cells. Assay of hormone level in the incubation media was performed in duplicates. The significance of differences between the control and experimental groups were evaluated by One-Way ANOVA and t-test using the statistical software Sigma Plot 11.0 (Jandel, Corte Madera, USA). The data are expressed as means ± SEM. Differences were compared for statistical significance at the P -level less than 0.05 (P≤0.05).
RESULTS
The effect of amygdalin on progesterone and estradiol-17β release by ovarian GCs
The secretory activity of granulosa cells (GCs) from cyclic porcine ovaries after amygdalin addition was observed (Figs. 2, 3) . The experimental application of amygdalin (1, 10, 100, 1000, 10 000 µg/mL) to granulosa cells culture did not cause significant (P≥0.05) changes in the progesterone release, compared to the control without addition of the substance (Fig. 2) . However, an apparent stimulation of the estradiol-17β release by GCs after amygdalin application was detected (Fig. 3) . The significant (P≤0.05) increase of the estradiol-17β-release by GCs was detected in experimental group with the highest used amygdalin dose (10 000 µg/mL), compared to the control untreated cells. On the other hand, no significant (P≥0.05) differences in release of estradiol-17β by ovarian GCs after lower amygdalin doses (1, 10, 100, 1000 µg/mL) were determined. Only slight increase of estradiol-17β release by GCs was detected in experimental groups received 10 and 100 µg/mL of amygdalin, compared to the control.
Figure 2
The effect of amygdalin on progesterone release by porcine ovarian granulosa cells. The control represents culture media without amygdalin addition; the experimental groups represent culture media supplemented with amygdalin (1, 10, 100, 1000, 10 000 µg/mL) addition. Differences between the groups were evaluated by One-way ANOVA, t-test. The data are expressed as means ± SEM. ELISA.
Figure 3
The effect of amygdalin on estradiol-17β release by porcine ovarian granulosa cells. The control represents culture medium without amygdalin addition; the experimental groups represent culture media supplemented with amygdalin (1, 10, 100, 1000, 10 000 µg/mL) addition Signs a, b denote value significantly (P <0.05) different from control group. Significance of differences between the groups was evaluated by One ANOVA, t-test. The data are expressed as means ± SEM. ELISA.
DISCUSSION
In the present report, hormone response of the porcine ovarian granulosa cells to amygdalin addition in vitro was examined. Granulosa cells (GCs), isolated from porcine cyclic ovaries, were able to survive, grow in culture and release the steroid hormones after the experimental addition of natural compound amygdalin. Results from this observation suggest possible stimulatory effect of the plant glycoside amygdalin on the release of steroid regulatory molecule (estradiol-17β) by GCs, but not progesterone, in a dosedependent manner. Amygdalin was one of the most popular, non-conventional, anti-cancer treatments in the 1970s. By 1978, 70 ,000 US cancer patients had used amygdalin to treat their cancer (Moss, 2005) . Still, evidence based research on amygdalin is sparse and its benefit controversial. Proponents consider amygdalin a natural cancer cure, whereas opponents warn that amygdalin is ineffective and even toxic. Although it has been argued that amygdalin is unsafe, no serious acute toxicity has been encountered (Makarević et al., 2014) . Schmidt et al. (1978) demonstrated that oral administration of amygdalin in doses equivalent to the recommended human tumoricidial doses along with the sweet almond preparations containing the amygdalin-hydrolyzing enzyme complex emulsion produced high levels of HCN in serum, clinical signs of cyanide toxicity, and death of 6 of 10 experimental animals. Study focused on the therapeutic effect of amygdalin on various malignant human disease was carried out by Moertel et al. (1982) . No substantive benefit was observed in terms of cure, improvement, or stabilization of cancer, improvement of symptoms related to cancer, or extension of life span. The hazards of amygdalin therapy were evidenced several patients by symptoms of cyanide toxicity. On the other hand, unique results were observed in recent study that described inhibitory action of amygdalin on cervical cancer cells. In this study, amygdalin was able to inhibit the growth of human cervical cancer cell line (HeLa cells) both in vitro and also in vivo through a mechanism of inducing apoptosis. Authors concluded, amygdalin may serve as a potentially effective therapy for cervical cancer (Chen et al., 2013) . Similarly, influence of amygdalin on the tumor growth, proliferation and cell cycle progression of bladder cancer cells was investigated by Makarevic et al. (2014) . The suppression of cdk2 and cyclin A, key molecules responsible for cell cycle progression and cell division, was suggested as revelant mechanism defining how amygdalin may arrest or diminish tumor growth and proliferation. Otherwise, cultured human bladder cancer cells were treated with amygdalin alone or a combination of amygdalin and an antibody that was coupled (chemically) to betaglucosidase. The target for this antibody was the glycoprotein (a protein with sugar molecules attached) MUC1. In this study, amygdalin alone was not very effective in killing the bladder cancer cells, but its cell-killing ability was 36 times greater in the presence of the antibody-enzyme complex (Syrigos et al.,  1998) . However, the question whether amygdalin is able to affect the cellular processes in normal tissues, under physiological conditions, is still unanswered. Therefore, uncertain outcomes have led us to evaluate the possible impact of amygdalin on the secretory activity of healthy ovarian granulosa cells in vitro. In our study, the noticeable changes in estradiol-17β release by ovarian GCs were determined after the amygdalin addition. Amygdalin, at the highest dose (10 000 µg/mL), stimulated the release of estradiol-17β by GCs, in comparison to the untreated control cells. On the contrary, no significant changes in the progesterone release by GCs caused by amygdalin addition were observed in this study. These results are in accordance with our previous investigation, in which has described the amygdalin influence on the release of progesterone by GCs from cyclic and also non-cyclic porcine ovaries in vitro. No significant differences in the progesterone release by GCs from cyclic and non-cyclic ovaries after amygdalin treatment (1, 10, 100, 1000, 10 000 µg/mL) were detected (Halenár et  al., 2013a) , 2003; Randel et al., 1992) . Likewise, cultured HTB-35 cells line, as a model of cervical carcinoma, was used for the evaluation anticancer properties of amygdalin. Results from this study indicate that amygdalin reduced proliferation potential, decreased mitochondrial activity, accumulated cells in the G1 phase and lead to their death (Jarocha and Majka, 2011) . Recent observation, carried out by Nabavizadeh et al. (2011) , has also suggested the preventive and therapeutic effects of amygdalin on absolute alcohol-induced gastric ulcer in rats. The results of this study showed that amygdalin protected gastric mucosa from alcohol-induced gastric ulcer, and the protective action was mediated via gastric mucosal nitric oxide production and TNF-α suppression. There are many studies which have described the effects of different natural substances on the secretory activity of porcine (Medveďová et Results from this in vitro study suggested that reproductive toxicity of animals induced by a mycotoxin -deoxynivalenol can be inhibited by a protective natural substance -resveratrol. Amygdalin, as a therapeutic agent, has not yet received FDA approval for use in the United States owing to insufficient clinical verification of its therapeutic efficacy, and the anticancer effect of amygdalin remains controversial (Hwang et al., 2008) . Possible modulatory impact of amygdalin (only high doses) on the steroid production of porcine ovaries is presented here.
CONCLUSION
Predictable impact of reputed anticancer compound amygdalin on the release of steroid hormones by GCs from porcine cyclic ovaries was demonstrated in this report. The amygdalin application (various doses) to ovarian GCs caused a dosedependent stimulation of estradiol-17β release. On the contrary, no differences in the progesterone release by ovarian GCs were obtained after amygdalin addition, compared to untreated control cells. In conclusion, results obtained from this in vitro study, together with our ongoing animal study, could significantly contribute to evaluate the possible effects of amygdalin on healthy animal system. secretion activity, markers of proliferation and apoptosis of porcine ovarian granulosa cells in vitro. 
